Kyle Munz

Patrick Vermersch, MD, PhD, University of Lille, France details the adverse events observed in the frexalimab trials and the next steps necessary to establish frexalimab as a standard of care in multiple sclerosis (MS) in the third and final part of an interview.

Results from a retrospective cohort study analyzing patients with breast cancer bolster reports of an association between radiation therapy and subsequent risks of skin cancers.

A cross-sectional study did not find significant associations between sleep health and consumption of caffeine from coffee or tea in older adults.

A retrospective, qualitative cohort study concludes that patients with sickle cell disease (SCD) may have been negatively impacted by the 2016 CDC guidance.

A placebo-controlled, double-blind, randomized study suggested that the consumption of yeast mannan may benefit sleep quality and gut health.

Results from this cohort study found that levels of glial fibrillary acid protein, cerebral spinal fluid, and neurofilament heavy chain are distinguishable biomarkers that are associated with disease outcomes in multiple sclerosis (MS).

A multicentric, single-arm diagnostic study created a decentralized federated learning model for the classification of invasive melanomas and nevi, showcasing comparable results to centralized data models.

A descriptive, qualitative study investigated the experiences and perspectives of patients with venous thromboembolism on shared decision-making and treatment with anticoagulants.

A retrospective, cross-sectional study analyzed national trends of immunohistochemistry (IHC) use in the diagnosis of melanoma.

A large population-based study revealed the associations between sleep-disordered breathing (SDB) and risk for hypertension and diabetes through the use of metabolomic profiling.

A single-center, retrospective study examined the management of thrombotic events in patients presenting with thrombocytopenia following vaccination against COVID-19.

The FDA has declined to approve glatiramer acetate (GA) depot in the treatment of relapsing types of multiple sclerosis (MS), issuing a complete response letter (CRL) for the long-acting, injectable form of GA.

A single-center, retrospective study demonstrated the major success of immunosuppressive therapies in contributing to complete remission in patients with acquired hemophilia A.

A comparative analysis on skin cancer management guidelines in the US highlights the necessity of further research in this subject.

Patrick Vermersch, MD, PhD, University of Lille, France discusses the next steps in frexalimab trials and the findings that have surprised him the most thus far, the second part of an interview.

A case-control study finds altered sleep events and characteristics exhibited in elderly patients with epilepsy compared to younger patients with epilepsy, as well as those without.

The poster session at the Americas Committee for Research and Treatment in Multiple Sclerosis (ACTRIMS) Forum 2024 dedicated a section to emerging developments in the use of artificial intelligence (AI) in research and treatment approaches in multiple sclerosis (MS).

Speakers on the final day of the Americas Committee for Research and Treatment in Multiple Sclerosis (ACTRIMS) Forum 2024 discussed advancements in rehabilitation trials in multiple sclerosis (MS) and unmet research needs.

On day 2 of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2024, speakers gave great attention to novel developments in the field of imaging and 3D modeling in multiple sclerosis (MS).

Young investigators spoke to emerging metabolic and cognitive research in multiple sclerosis (MS) at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2024.

Speakers at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2024 focused their attention on avenues to improve research accessibility for investigators and care access for patients with multiple sclerosis (MS).

The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2024 opened with discussions on the novel concepts emerging in multiple sclerosis (MS) research, such as the associations between synaptic loss and hypoxia with disease progression.

Advocates for health insurance reform indicate the need to make system-wide, policy-level changes to improve patient outcomes, which include investing in improved access to care and lowering the burden of administrative costs.

An ecological study revealed increasing rates of skin cancer overdiagnosis in white Americans.

A cross-sectional study analyzing morphological and dimensional features of palatal rugae patters revealed that distinct anomalies exist in children with sickle cell disease (SCD) compared with children without.

The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) will host its ninth annual meeting in West Palm Beach, Florida, from February 29 to March 2, 2024, to address a plethora of barriers faced by patients and clinicians managing multiple sclerosis (MS).

Patrick Vermersch, MD, PhD, joined The American Journal of Managed Care® for an interview on promising data from a phase 2 clinical trial on frexalimab in the treatment of multiple sclerosis (MS) and associated neurodegeneration.

A meta-analysis on complement inhibitors in the management of paroxysmal nocturnal hemoglobinuria (PNH) reveals an association between these interventions and positive treatment outcomes.

Andrew Ress, MD, discusses the novel integration of artificial intelligence (AI) into the skin cancer treatment landscape.

A bidirectional Mendelian randomization (MR) study found a casual relationship between sleep-related phenotypes (SRPs) and gut microbiota.